维生素D_(3)联合小儿肺热咳喘颗粒治疗小儿支气管哮喘的临床效果

Clinical Effect of Vitamin D_(3) Combined with Pediatric Pulmonary Heat Cough and Asthma Granules in the Treatment of Pediatric Bronchial Asthma

目的探讨维生素D_(3)联合小儿肺热咳喘颗粒治疗小儿支气管哮喘(BA)的临床效果。方法选取2022年1月—2023年5月该院收治的94例BA患儿为研究对象,以随机数字表法将其分为研究组(n=47)和对照组(n=47)。对照组采用小儿肺热咳喘颗粒治疗,研究组采用维生素D_(3)联合小儿肺热咳喘颗粒治疗。对比两组临床疗效、哮喘控制情况、肺功能、血清变态反应指标、不良反应发生情况。结果研究组治疗总有效率为95.74%,高于对照组的80.85%,差异有统计学意义(P<0.05)。治疗前,两组儿童哮喘控制测试(C-ACT)评分比较,差异无统计学意义(P>0.05);治疗后,研究组C-ACT评分为(24.28±2.76)分,高于对照组的(22.15±1.90)分,差异有统计学意义(P<0.05)。治疗前,两组呼气峰流量(PEF)、第1秒用力呼气容积(FEV_(1))比较,组间差异无统计学意义(P>0.05);治疗后,研究组PEF、FEV_(1)分别为(3.86±0.62)L/s、(1.61±0.19)L,均大于对照组的(3.57±0.55)L/s、(1.49±0.16)L,组间差异有统计学意义(P<0.05)。治疗前,两组白三烯B4(LTB4)、单核细胞趋化蛋白-1(MCP-1)水平比较,组间差异无统计学意义(P>0.05);治疗后,研究组LTB4、MCP-1水平分别为(34.73±6.28)ng/L、(58.52±6.16)pg/mL,均低于对照组的(47.11±5.04)ng/L、(64.17±5.92)pg/mL,组间差异有统计学意义(P<0.05)。研究组不良反应发生率为4.26%,与对照组的8.51%比较,差异无统计学意义(P>0.05)。结论维生素D_(3)联合小儿肺热咳喘颗粒治疗小儿BA能够促进临床疗效提高,改善哮喘控制情况,提高肺功能,调节血清变态反应指标,具有较高安全性。

Objective To explore the clinical effect of vitamin D_(3) combined with Xiao'er Feire Kechuan Granules in the treatment of pediatric bronchial asthma(BA).Methods 94 children with BA from January 2022 to May 2023 who were admitted in the hospital were selected as the research objects,and they were randomly divided into a study group(n=47)and a control group(n=47).The control group was treated with Xiao'er Feire Kechuan Granules,the study group was treated with Vitamin D_(3) combined with Xiao'er Feire Kechuan Granules inhalation.The clinical efficacy,asthma control,lung function,serum allergy markers,and adverse reactions in both groups were compared.Results The total effective rate of the study group was 95.74%,which was higher than 80.85%of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the Child Asthma Control Test(C-ACT)score between the two groups(P>0.05);after treatment,the C-ACT score of the study group was(24.28±2.76)points,higher than(22.15±1.90)points of the control group,and the difference between the groups was statistically significant(P<0.05).There was no statistically significant difference in peak expiratory flow(PEF)and forced expiratory volume in the first second(FEV_(1))between the two groups(P>0.05),after treatment,the PEF and FEV_(1) of the study group were(3.86±0.62)L/s and(1.61±0.19)L,higher than(3.57±0.55)L/s and(1.49±0.16)L of the control group,with statistically significant differences between the groups(P<0.05).Before treatment,there was no statistically significant difference in the levels of Leukotriene B4(LTB4)and monocyte chemotactic protein-1(MCP-1)between the two groups(P>0.05),after treatment,LTB4 and MCP-1 levels in the study group were(34.73±6.28)ng/L and(58.52±6.16)pg/mL,lower than(47.11±5.04)ng/L and(64.17±5.92)pg/mL of the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the study group was 4.26%,and there was no statistically significant difference compared to the control group's 8.51%(P>0.05).Conclusion The combination of vitamin D_(3) and Xiao'er Feire Kechuan granules can promote clinical efficacy,improve asthma control,enhance lung function,regulate serum allergic reaction indicators,and have high safety in the treatment of pediatric BA.